Neopterin as a biomarker of immune response in cancer patients

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11150%2F17%3A10364342" target="_blank" >RIV/00216208:11150/17:10364342 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11160/17:10364342 RIV/00179906:_____/17:10364342 RIV/61989592:15110/17:73583804

Výsledek na webu

<a href="http://atm.amegroups.com/article/view/15415/html" target="_blank" >http://atm.amegroups.com/article/view/15415/html</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.21037/atm.2017.06.29" target="_blank" >10.21037/atm.2017.06.29</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Neopterin as a biomarker of immune response in cancer patients

Popis výsledku v původním jazyce

With the advent of immunotherapy the topic of biomarkers of immune response is of high interest. Along with the expression of programmed death ligand 1 (PD-L1) or tumor infiltrating lymphocytes (TIL), biomarkers of macrophage activation could be of interest. Neopterin is a biomarker of immune activation increased in different disorders associated with immune activation, including cancer. Neopterin synthesis is induced by interferon-gamma. that also induces indoleamine 2,3-dioxygenase (IDO), an enzyme catalyzing catabolism of tryptophan to kynurenine. Increased urinary or serum concentrations of neopterin have been associated with poor prognosis across a spectrum of malignant disorders of different primary location. Neopterin concentration in peripheral blood as well as in the tumor microenvironment correlates with phenotypic and functional changes of lymphocytes, indicating immune dysfunction. Increased neopterin concentrations are also accompanied by increased rate of conversion of tryptophan to kynurenine. Increasing neopterin concentrations also accompany side effects of anticancer treatment and could predict subsequent complications. Although almost four decades have elapsed since the discovery of increased neopterin concentrations in cancer patients, the full potential of neopterin as a biomarker in this setting has not been so far realized.

Název v anglickém jazyce

Neopterin as a biomarker of immune response in cancer patients

Popis výsledku anglicky

With the advent of immunotherapy the topic of biomarkers of immune response is of high interest. Along with the expression of programmed death ligand 1 (PD-L1) or tumor infiltrating lymphocytes (TIL), biomarkers of macrophage activation could be of interest. Neopterin is a biomarker of immune activation increased in different disorders associated with immune activation, including cancer. Neopterin synthesis is induced by interferon-gamma. that also induces indoleamine 2,3-dioxygenase (IDO), an enzyme catalyzing catabolism of tryptophan to kynurenine. Increased urinary or serum concentrations of neopterin have been associated with poor prognosis across a spectrum of malignant disorders of different primary location. Neopterin concentration in peripheral blood as well as in the tumor microenvironment correlates with phenotypic and functional changes of lymphocytes, indicating immune dysfunction. Increased neopterin concentrations are also accompanied by increased rate of conversion of tryptophan to kynurenine. Increasing neopterin concentrations also accompany side effects of anticancer treatment and could predict subsequent complications. Although almost four decades have elapsed since the discovery of increased neopterin concentrations in cancer patients, the full potential of neopterin as a biomarker in this setting has not been so far realized.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

10406 - Analytical chemistry

Projekt

<a href="/cs/project/NV16-32030A" target="_blank" >NV16-32030A: Využití disulfiramu v nové roli léčebného prostředku pro rekurentní metastatické nádory prsu rezistentní na chemo a endokrinní terapii</a><br>

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2017

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Annals of Translational Medicine

ISSN

2305-5839

e-ISSN

—

Svazek periodika

5

Číslo periodika v rámci svazku

13

Stát vydavatele periodika

CN - Čínská lidová republika

Počet stran výsledku

12

Strana od-do

—

Kód UT WoS článku

000408647900013

EID výsledku v databázi Scopus

2-s2.0-85024884256